Heart Failure With Preserved Ejection Fraction (HFpEF) Clinical Trial
Official title:
A Phase 1 Single Center Open-label, Non-randomized, Fixed Sequence Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of AZD9977 When Administered Alone and With Itraconazole
This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole.
This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole. Two types of treatments (treatment period 1 and treatment period 2) will be administered in a fixed order separated by a washout period of 3 days or more. Treatment period 1 will be single dose of AZD9977 (Dose 1) administration, in the fed state, on Day 1 followed by at least 3 days washout period. For treatment period 2, Itraconazole will be administered daily (Dose 2) from Day 4 to Day 8 plus AZD9977 (Dose 1, fed state) will be administered as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
| Recruiting |
NCT05441839 -
UK Heart Failure With Preserved Ejection Fraction
|
||
| Completed |
NCT01989299 -
Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction
|
||
| Terminated |
NCT03909295 -
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
|
Phase 3 | |
| Completed |
NCT04327024 -
Study of Verinurad in Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
| Active, not recruiting |
NCT05136820 -
Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study
|
N/A | |
| Completed |
NCT03988634 -
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
|
Phase 3 | |
| Recruiting |
NCT03876223 -
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
|
||
| Completed |
NCT04232345 -
A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT05792059 -
DevElopMent of Clinical PATHwaYs to the Diagnosis of Heart Failure With Preserved Ejection Fraction
|
||
| Completed |
NCT01714752 -
Evaluation of Left Ventricular Filling Pressures During Exercise
|
N/A | |
| Completed |
NCT06036186 -
Study for the Treatment of Heart Failure With Preserved Ejection Fraction Associated With High Blood Pressure Using Right Atrial Pacing Controlled by the PressurePaceTM System
|
N/A | |
| Recruiting |
NCT05383287 -
Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)
|
||
| Completed |
NCT03877224 -
DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
|
Phase 3 | |
| Active, not recruiting |
NCT04847557 -
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
|
Phase 3 | |
| Recruiting |
NCT04822649 -
Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition
|
N/A |